Novo Nordisk Stock Rises as Q4 Wegovy Sales More Than Double Despite Slower 2025 Growth Outlook
Novo Nordisk’s (NVO) U.S.-listed shares surged 4% in premarket trading after the Danish pharmaceutical giant reported better-than-expected fourth-quarter results. The maker of popular weight-loss drugs Ozempic and Wegovy posted a 30% year-over-year sales increase, reaching 85.68 billion Danish kroner ($11.97 billion), surpassing analyst estimates of DKK80.62 billion. Profit also exceeded expectations, coming in at DKK28.23 billion.
Wegovy Drives Strong Growth
Sales of Wegovy skyrocketed 107% at constant exchange rates, hitting DKK19.87 billion, slightly below projections. Ozempic, another key product, grew by 12% to DKK33.85 billion, outperforming forecasts. Despite these impressive figures, Novo Nordisk projects a slower sales growth for 2025, estimating a rise of 16% to 24% at constant exchange rates, down from 26% in 2024.
Challenges Ahead with Growing Competition
The company attributed its conservative outlook to "intensifying competition and continued pricing pressure" in the diabetes and obesity care markets. Novo Nordisk faces stiff rivalry from Eli Lilly, the maker of Mounjaro and Zepbound, which has been expanding its footprint in the weight-loss drug sector.Looking to the Future with CagriSema
CEO Lars Fruergaard Jorgensen emphasized the company's focus on commercial execution, research and development, and production expansion in 2025. Novo Nordisk also announced plans to file for the first regulatory approval of its new weight-loss drug, CagriSema, in the first quarter of 2026. This move comes after disappointing trial results impacted the company’s stock in December.Despite recent volatility, Novo Nordisk’s strong Q4 performance highlights its resilience in a competitive landscape, with growth opportunities on the horizon driven by its expanding drug portfolio.
No Comment to " Novo Nordisk Stock Rises as Q4 Wegovy Sales More Than Double Despite Slower 2025 Growth Outlook "